Авторы

  • Babajanova G.B.

Ключевые слова:

Epstein–Barr virus; autoimmunity; chronic inflammation; molecular mimicry; immune evasion; multiple sclerosis; rheumatoid arthritis; biomarkers; immunotherapy.

Библиографические ссылки

1. Münz C. Latency and lytic replication in the oncogenesis of the Epstein-Barr virus. Nat Rev Microbiol. 2019;17:691–700. doi:10.1038/s41579-01 9-0244-2.

2. Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185(20):3652–3670. doi:10.1016/j.cell.2022. 08.026.

3. Albanese M, Tagawa T, Hammerschmidt W. Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host. Front Microbiol. 2022;13:955603. doi:10.3389/fmicb.2022.955 603.

4. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578): 296–301. doi:10.1126/science.abj8222.

5. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603:321–327. doi:10.1038/s41586-022-04432-7.

6. Yao Y, Kong W, Yang L, Ding Y, Cui H. Immunity and immune evasion mechanisms of Epstein-Barr virus. Viral Immunol. 2023;36(5):303–317. doi:10.1089/vim.2022.0200.

7. Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023; 21(1):51–64. doi:10.1038/s41579-022-00770-5.

8. Bjornevik K, Münz C, Cohen JI, Ascherio A. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19:160–171. doi:10.1038/s41582-023-00775-5.

9. Lanz TV, Robinson WH, Ho PP, Steinman L. Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials. Clin Transl Immunology. 2023;12(2). doi:10.1002/cti2. 1438.

10. Sausen DG, Poirier MC, Spiers LM, Smith EN. Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival. Front Immunol. 2023;14:1289313. doi:10.3389/fimmu.2023.12 89313.

11. Fechtner S, Berens H, Bemis E, Johnson RL, Guthridge CJ, Carlson NE, et al. Antibody responses to Epstein-Barr virus in the preclinical period of rheumatoid arthritis suggest the presence of increased viral reactivation cycles. Arthritis Rheumatol. 2022;74(4):597–603. doi:10.1002/art.41994.

12. Ball RJ, Avenell A, Aucott L, Hanlon P, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and

13. Zhao Y, Zhang Q, Zhang B, Dai Y, Gao Y, Li C, et al. Epstein-Barr viruses: their immune evasion strategies and implications for autoimmune diseases. Int J Mol Sci. 2024;25(15):8160. doi:10.3390/ ijms25158160.

14. Robinson WH, Younis S, Love ZZ, Steinman L, Lanz TV, et al. Epstein-Barr virus as a potentiator of autoimmune diseases. Nat Rev Rheumatol. 2024;20:729–740. doi:10.1038/s41584-024-01167-9.

15. Borghol AH, Bitar ER, Hanna A, Naim G, Rahal EA. The role of Epstein-Barr virus in autoimmune and autoinflammatory diseases. Crit Rev Microbiol. 2025;51(2):296–316. doi:10.1080/1040841X.2024.2344114.

16. Morawiec N, Adamczyk B, Spyra A, Herba M, Boczek S, Korbel N, et al. The role of Epstein-Barr virus in the pathogenesis of autoimmune diseases. Medicina (Kaunas). 2025;61(7):1148. doi:10.3390/ medicina61071148.

17. Li SY, Jia J, Xu LZ, Zheng K. Relationship between Epstein-Barr virus and inflammatory bowel disease. World J Gastroenterol. 2025;31(48):1111 87. doi:10.3748/wjg.v31.i48.111187.

18. Münz C. Epstein-Barr virus pathogenesis and emerging control strategies. Nat Rev Microbiol. 2025;23(10):667–679. doi:10.1038/s41579-025-01 181-y.

19. Zane GK, Sutton A, Brumwell A, Hossain MR, Hawes SE, Giovannoni G, et al. The path to prevention of multiple sclerosis: considerations for Epstein-Barr virus vaccine-based prevention studies. Mult Scler. 2025. doi:10.1177/13524585251340 812.

20. Shabnam F, Khan G. Mechanisms of Epstein-Barr virus-associated autoimmunity: a comparative overview. Front Immunol. 2026;17:189 1373. doi:10.3389/fimmu.2026.1891373.